Related Experiment Videos
Beta-blockers in chronic treatment after acute myocardial infarction
1Department of Internal Medicine and Therapeutics, Policlinico S. Matteo, University of Pavia, Italy.
Insights
Beta-blockers significantly reduce cardiac mortality and reinfarction after myocardial infarction (MI). Those without intrinsic sympathomimetic activity (ISA) appear more effective, especially for high-risk patients, suggesting long-term use is beneficial.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers are established post-myocardial infarction (MI) treatments.
- Their cardioprotective effects include antiarrhythmic and anti-ischemic actions.
- Intrinsic sympathomimetic activity (ISA) may influence beta-blocker efficacy.
Purpose of the Study:
- To review the benefits of beta-blockers after MI.
- To compare the efficacy of beta-blockers with and without ISA.
- To identify patient subgroups that benefit most from beta-blocker therapy.
Main Methods:
- Review of postinfarction treatment trials.
- Analysis of outcomes including cardiac mortality and reinfarction.
- Comparison of beta-blockers with and without ISA.
Main Results:
- Beta-blockers significantly reduce post-MI cardiac mortality and nonfatal reinfarction.
- Beta-blockers without ISA appear more effective in reducing cardiac mortality than those with ISA.
- High-risk, elderly, and hypertensive patients may derive the greatest benefit.
Conclusions:
- Continuous postinfarction beta-blocker therapy is supported by recent long-term trial data.
- Beta-blockers remain a cornerstone of post-MI management.
- Further research may clarify optimal duration and patient selection for beta-blocker therapy.
Abstract:
Postinfarction treatment trials have demonstrated that beta-blockers are beneficial after myocardial infarction (MI), significantly reducing postinfarction cardiac mortality and nonfatal reinfarction, aside from bringing about an improved quality of life. Such cardioprotective action is probably mediated by both antiarrhythmic and anti-ischemic effects of these drugs. Beta-Blockers without ISA seem to be more effective in reducing cardiac mortality than those with ISA, which is probably due to their different effects on heart rate. Patients deriving major benefit from beta-blocker therapy after MI should be "high risk," elderly, and, perhaps, hypertensive patients. The suitable duration of postinfarction beta-blocker therapy is unknown: results from recent long-term trials speak in favor of continuous postinfarction beta-blocker therapy.